APA (7th ed.) Citation

VS, S., L, K., Y, L., Y, D., H, L., LE, L., . . . DZI, C. (2026). Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial. Hypertension (Dallas, Tex. : 1979), 83(2), e25955. https://doi.org/10.1161/HYPERTENSIONAHA.125.25955

Chicago Style (17th ed.) Citation

VS, Sridhar, et al. "Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial." Hypertension (Dallas, Tex. : 1979) 83, no. 2 (2026): e25955. https://doi.org/10.1161/HYPERTENSIONAHA.125.25955.

MLA (9th ed.) Citation

VS, Sridhar, et al. "Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial." Hypertension (Dallas, Tex. : 1979), vol. 83, no. 2, 2026, p. e25955, https://doi.org/10.1161/HYPERTENSIONAHA.125.25955.